Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection
Melbourne Health
100 participants
Aug 1, 2019
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
Eligibility
Inclusion Criteria2
- Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care.
- Able to give informed consent.
Exclusion Criteria1
- Unable to give informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03717623